Asymmetric Total Synthesis and Revision of Absolute Stereochemistry for (+)-Taumycin A: An Approach that Exploits Orthogonally Protected Quasienantiomers.

The first asymmetric total synthesis of C(9)-S-(+)-taumycin A is now reported using an approach that targeted both C(9) diastereomers concurrently. To facilitate this work, we called upon the symmetrical nature of a C(5)-C(13) side-chain intermediate and exploited orthogonal protecting groups as a tactic to access both stereoisomers from a single chiral, nonracemic intermediate. In addition to our successful approach, several minor detours that helped refine our strategy and a detailed analysis of 1H NMR data will be discussed. Select compounds included in this work were screened against the NCI60 cell line panel and displayed modest growth inhibition activity.

Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins.

Anti-apoptotic Bcl-2 family proteins are overexpressed in a wide spectrum of cancers and have become well validated therapeutic targets. Cancer cells display survival dependence on individual or subsets of anti-apoptotic proteins that could be effectively targeted by multimodal inhibitors. We designed a 2,5-substituted benzoic acid scaffold that displayed equipotent binding to Mcl-1 and Bfl-1. Structure-based design was guided by several solved cocrystal structures with Mcl-1, leading to the development of compound 24, which binds both Mcl-1 and Bfl-1 with Ki values of 100 nM and shows appreciable selectivity over Bcl-2/Bcl-xL. The selective binding profile of 24 was translated to on-target cellular activity in model lymphoma cell lines. These studies lay a foundation for developing more advanced dual Mcl-1/Bfl-1 inhibitors that have potential to provide greater single agent efficacy and broader coverage to combat resistance in several types of cancer than selective Mcl-1 inhibitors alone.